Title: Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation
Authors: Clancy, J P ×
Rowe, Steven M
Accurso, Frank J
Aitken, Moira L
Amin, Raouf S
Ashlock, Melissa A
Ballmann, Manfred
Boyle, Michael P
Bronsveld, Inez
Campbell, Preston W
De Boeck, Christiane
Donaldson, Scott H
Dorkin, Henry L
Dunitz, Jordan M
Durie, Peter R
Jain, Manu
Leonard, Anissa
McCoy, Karen S
Moss, Richard B
Pilewski, Joseph M
Rosenbluth, Daniel B
Rubenstein, Ronald C
Schechter, Michael S
Botfield, Martyn
Ordoñez, Claudia L
Spencer-Green, George T
Vernillet, Laurent
Wisseh, Steve
Yen, Karl
Konstan, Michael W #
Issue Date: Jan-2012
Publisher: British Medical Association
Series Title: Thorax vol:67 issue:1 pages:12-18
Abstract: VX-809, a cystic fibrosis transmembrane conductance regulator (CFTR) modulator, has been shown to increase the cell surface density of functional F508del-CFTR in vitro.
ISSN: 0040-6376
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Pediatric Pulmonology Section (-)
Screening, Diagnostics and Biomarkers (-)
× corresponding author
# (joint) last author

Files in This Item:

There are no files associated with this item.

Request a copy


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science